Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare reimbursement swings, rapid acquisitions, and intricate lease accounting make AdaptHealth Corp鈥檚 disclosures some of the most difficult in the home-health sector. If you have ever tried to locate segment revenue shifts or pinpoint when executives sell shares, you know the challenge of AdaptHealth SEC filings explained simply.
Stock Titan solves that complexity. Our AI reads each AdaptHealth annual report 10-K simplified and every AdaptHealth quarterly earnings report 10-Q filing the instant it hits EDGAR, highlighting reimbursement exposure, acquisition earn-outs, and goodwill adjustments. AG真人官方-time alerts surface AdaptHealth Form 4 insider transactions real-time, so you never miss crucial AdaptHealth executive stock transactions Form 4. Need headline context? Our platform turns dense 8-Ks into one-screen briefs鈥攖hink 鈥淎daptHealth 8-K material events explained鈥�鈥攚hile proxy digests spotlight AdaptHealth proxy statement executive compensation in clear terms.
Use cases span the entire investment workflow:
- Monitor AdaptHealth insider trading Form 4 transactions before major announcements.
- Run comparative AdaptHealth earnings report filing analysis across quarters without slogging through PDFs.
- Speed-read footnotes by understanding AdaptHealth SEC documents with AI鈥攍ease liabilities, DSO trends, and integration costs surfaced automatically.
Whether you鈥檙e tracking oxygen equipment margins or gauging cash-flow impact from new payer contracts, Stock Titan provides comprehensive coverage of every 10-K, 10-Q, 8-K, S-4, and Form 4鈥攗pdated in real time and distilled into investor-ready language. Complex filings, clarified.
AdaptHealth Corp. (AHCO) 鈥� Form 4 insider activity
Director Theodore B. Lundberg reported two acquisitions of AdaptHealth common stock on 06/26/2025:
- 21,346 shares acquired
- 7,864 shares acquired
Both transactions are recorded at $0, indicating they were equity grants or similar non-cash awards rather than open-market purchases. Following the transactions, Lundberg鈥檚 direct beneficial ownership rose to 859,756 shares. No dispositions, derivative securities, or 10b5-1 plan designations were disclosed, and the filing lists a Power of Attorney (Exhibit 24) supporting the submission.
The Form 4 contains no additional financial metrics or narrative commentary.
ACCO Brands Corporation (ACCO) filed a Form 4 reporting insider activity by Senior Vice-President & Chief Information Officer Paul P. Daniel on 18 June 2025.
The executive acquired 1,332.4 Restricted Stock Units (RSUs) through dividend-equivalent accruals across three existing awards under the company鈥檚 Incentive Plan:
- 451.3 RSUs linked to an award vesting on 14 Mar 2026; cumulative units in that award now 21,092.7.
- 420.6 RSUs linked to an award vesting on 12 Mar 2027; cumulative units now 19,655.3.
- 460.5 RSUs linked to an award vesting on 11 Mar 2028; cumulative units now 21,518.2.
No shares were sold; the acquisition price is recorded as $0 because RSUs are granted, not purchased. Ownership remains direct (D). Each RSU converts 1-for-1 into common stock upon the stated vesting dates, contingent on continued employment and subject to plan acceleration provisions.
The filing represents routine incentive-plan activity and does not disclose any open-market transactions, amendments, or other material corporate events.
ACCO Brands Corporation (ACCO) filed a Form 4 reporting insider activity by Senior Vice-President & Chief Information Officer Paul P. Daniel on 18 June 2025.
The executive acquired 1,332.4 Restricted Stock Units (RSUs) through dividend-equivalent accruals across three existing awards under the company鈥檚 Incentive Plan:
- 451.3 RSUs linked to an award vesting on 14 Mar 2026; cumulative units in that award now 21,092.7.
- 420.6 RSUs linked to an award vesting on 12 Mar 2027; cumulative units now 19,655.3.
- 460.5 RSUs linked to an award vesting on 11 Mar 2028; cumulative units now 21,518.2.
No shares were sold; the acquisition price is recorded as $0 because RSUs are granted, not purchased. Ownership remains direct (D). Each RSU converts 1-for-1 into common stock upon the stated vesting dates, contingent on continued employment and subject to plan acceleration provisions.
The filing represents routine incentive-plan activity and does not disclose any open-market transactions, amendments, or other material corporate events.
SEC Form 4 filed on 06/30/2025 shows AdaptHealth Corp. (AHCO) director Gregory Belinfanti acquired a total of 28,086 common shares on 06/26/2025 through two transactions recorded at $0.00 per share, indicating stock awards rather than open-market purchases. His direct holdings rose from an estimated 45,408 shares to 73,494 shares after the grants. No derivative securities were reported. While the amount is modest relative to AHCO鈥檚 float, the additional ownership slightly tightens insider鈥搒hareholder alignment and is typically viewed as a mildly positive governance signal.
AdaptHealth Corp. (AHCO) filed a Form 4 reporting an insider equity transaction by director Dale B. Wolf. On 26 June 2025, Wolf acquired 21,346 shares of common stock at a stated price of $0.00, a typical indicator of a stock award or equity grant rather than an open-market purchase. Following the award, his direct holdings rose to 96,235 shares, up roughly 28% from the prior 74,889-share position. In addition, Wolf continues to hold 14,000 shares indirectly through the Dale B. Wolf Generation Skipping Trust, for which he serves as investment manager.
No shares were sold and no derivative securities were exercised. The filing therefore represents a modest, non-cash increase in insider ownership and adds limited incremental dilution to AdaptHealth鈥檚 share count. While insider grants do not carry the same signaling power as open-market purchases, they can still improve alignment between the director and outside shareholders, especially when the shares are retained rather than immediately sold. Investors may view the award as a neutral-to-slightly-positive governance development; however, its dollar value appears immaterial relative to the company鈥檚 market capitalization and is unlikely to have a meaningful impact on valuation or liquidity.
Form 4 filing for AdaptHealth Corp. (AHCO) reports that director David S. Williams III acquired 21,346 shares of common stock on 06/26/2025 at a stated price of $0.00 per share, suggesting the shares were received through an equity award or similar non-cash grant. Following the transaction, Williams now beneficially owns 58,245 shares, all held directly. No derivative securities or dispositions were disclosed, and the filing was signed on 06/30/2025 by an attorney-in-fact.
- Reporting person status: Director, single filer
- Transaction code: 鈥淎鈥� (acquisition)
- Ownership form: Direct
- No sales, derivative activity, or 10b5-1 plan indicated
AdaptHealth Corp. (AHCO) 鈥� Form 4 filing overview:
- Reporting person: Diana L. Nole, listed as a Director of AdaptHealth Corp.
- Transaction date: 06/26/2025.
- Security: Common Stock.
- Transaction type & size: Acquisition of 21,346 shares (code 鈥淎鈥�) at a reported price of $0 per share.
- Post-transaction holdings: 33,045 shares held directly.
- Form signing date: 06/30/2025, executed by attorney-in-fact Richard Rew.
No derivative securities were reported and no sales were disclosed. The filing reflects an increase in insider ownership, which may be interpreted by some investors as a sign of board-level confidence, although the dollar value and context of the grant are not provided in the document.
AdaptHealth Corp. (AHCO) filed a Form 4 reporting that director Bradley J. Coppens acquired 21,346 shares of common stock on 06/26/2025. The shares were recorded at a stated price of $0.00, indicating a grant or other non-cash issuance. Following the transaction, Coppens鈥� direct ownership stands at 77,346 AHCO shares. No derivative securities were reported, and no other officers or insiders were listed on this filing.
AdaptHealth Corp (AHCO) filed a Form 3 Initial Statement of Beneficial Ownership for Daniel Edward McFadden, who has been appointed as the company's Chief Business Systems Officer. The filing, dated June 28, 2025, discloses McFadden's initial beneficial ownership position in the company.
Key ownership details:
- McFadden beneficially owns 53,958 shares of common stock in the form of restricted stock units (RSUs)
- The ownership is held directly (D)
- The RSUs will be settled in common stock upon vesting
The filing was executed by Richard Rew as attorney-in-fact for Daniel McFadden on June 26, 2025. This Form 3 filing is required under Section 16(a) of the Securities Exchange Act of 1934 for new officers, directors, or beneficial owners of more than 10% of a company's securities.